Liraglutide Linked to Reduction in VAT, Improvement in β-Index

Share this content:
Liraglutide Linked to Reduction in VAT, Improvement in β-Index
Liraglutide Linked to Reduction in VAT, Improvement in β-Index

TUESDAY, Sept. 26, 2017 (HealthDay News) -- For obese individuals with prediabetes or early type 2 diabetes, liraglutide is associated with a greater reduction in visceral adipose tissue (VAT) and greater improvement in β-index, according to a study published online Sept. 14 in Diabetes Care.

Francesca Santilli, from the Center of Aging Science and Translational Medicine in Chieti, Italy, and colleagues randomized 62 metformin-treated obese subjects with prediabetes or newly diagnosed type 2 diabetes to liraglutide or lifestyle counseling.

The researchers found that the reduction in VAT was significantly higher in the liraglutide versus the lifestyle counseling arm (P = 0.028) after comparable weight loss, achieved by 20 patients per arm, and superimposable glycemic control, as reflected by hemoglobin A1c level, which was accompanied by greater improvement in β-index (P = 0.021). There were no differences in reduction of subcutaneous adipose tissue (P = 0.64). With liraglutide administration only there was a significant increase in insulin-like growth factor-II serum levels (P = 0.024), and the increase correlated with a decrease in VAT (P = 0.056) and an increase in the β-index (P = 0.012).

"Liraglutide effects on visceral obesity and β-cell function might provide a rationale for using this molecule in obese subjects in an early phase of glucose metabolism dysregulation natural history," the authors write.

One author disclosed financial ties to the pharmaceutical industry.

Abstract/Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!

Already a member?

Sign In Now »

Drug Lookup

Browse drugs by: BrandGenericDisease

Trending Activities

All Professions



Sign up for myCME e-newsletters


More in Home

FDA Approves First Drug for Rare Form of Rickets

FDA Approves First Drug for Rare Form of ...

Crysvita approved for adults and children ages 1 year and older with x-linked hypophosphatemia

High FGF-23 Linked to Recurrent Cardiac Events After ACS

High FGF-23 Linked to Recurrent Cardiac Events After ...

FGF-23 in top quartile independently linked to greater risk of CV death, heart failure hospitalization

Medical Cannabis Not Recommended for Sleep Apnea

Medical Cannabis Not Recommended for Sleep Apnea

American Academy of Sleep Medicine says evidence insufficient to recommend cannabis for apnea

is free, fast, and customized just for you!

Already a member?

Sign In Now »